Experimental Therapeutics for Friedreich's Ataxia

Genetic Instabilities and Neurological Diseases

Volumn , Issue , 2006, Pages 297-303

  Wilson, Robert B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750742388     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369462-1/50019-3     Document Type: Chapter

References (47)

1. Pandolfo M. Friedreich's ataxia. Genetic Instabilities and Neurological Diseases 2006, Ch. 17, Elsevier, Burlington, MA. 2nd ed. R.D. Wells, T. Ashizawa (Eds.).
2. Patel P.I., Isaya G. Friedreich ataxia: From GAA triplet-repeat expansion to frataxin deficiency. Am. J. Hum. Genet. 2001, 69:15-24.
3. Adamec J., Rusnak F., Owen W.G., Naylor S., Benson L.M., Gacy A.M., Isaya G. Iron-dependent self-assembly of recombinant yeast frataxin: Implications for Friedreich ataxia. Am. J. Hum. Genet. 2000, 67:549-562.
4. Cavadini P., O'Neill H.A., Benada O., Isaya G. Assembly and iron-binding properties of human frataxin the protein deficient in Friedreich ataxia. Hum. Mol. Genet. 2002, 11:217-227.
5. Gakh O., Adamec J., Gacy A.M., Twesten R.D., Owen W.G., Isaya G. Physical evidence that yeast frataxin is an iron storage protein. Biochemistry 2002, 41:6798-6804.
6. Muhlenhoff U., Richhardt N., Ristow M., Kispal G., Lill R. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. 2002, 11:2025-2036.
7. Muhlenhoff U., Gerber J., Richhardt N., Lill R. Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p. EMBO J. 2003, 22:4815-4825.
8. Babcock M., de Silva D., Oaks R., Davis-Kaplan S., Jiralerspong S., Montermini L., Pandolfo M., Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997, 276:1709-1712.
9. Delatycki M.B., Camakaris J., Brooks H., Evans-Whipp T., Thorburn D.R., Williamson R., Forrest S.M. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 1999, 45:673-675.
10. Puccio H., Simon D., Cossee M., Criqui-Filipe P., Tiziano F., Melki J., Hindelang C., Matyas R., Rustin P., Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 2001, 27:181-186.
11. Horton A.A., Fairhurst S. Lipid peroxidation and mechanisms of toxicity. CRC Crit. Rev. Toxicol. 1987, 18:27-79.
12. Wilson R.B., Roof D.M. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat. Genet. 1997, 16:352-357.
13. Foury F., Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 1997, 411:373-377.
14. Radisky D.C., Babcock M.C., Kaplan J.K. The yeast frataxin homologue mediates mitochondrial iron efflux: Evidence for a mitochondrial iron cycle. J. Biol. Chem. 1999, 274:4497-4499.
15. Foury F. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. 1999, 456:281-284.
16. Rotig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A., Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich's ataxia. Nat. Genet. 1997, 17:215-217.
17. Bradley J.L., Blake J.C., Chamberlain S., Thomas P.K., Cooper J.M., Schapira A.H. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 2000, 9:275-282.
18. Lodi R., Hart P.E., Rajagopalan B., Taylor D.J., Crilley J.G., Bradley J.L., Blamire A.M., Manners D., Styles P., Schapira A.H.V., Cooper J.M. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. 2001, 49:590-596.
19. Schulz J.B., Dehmer T., Schols L., Mende H., Hardt C., Vorgerd M., Burk K., Matson W., Dichgans J., Beal M.F., Bogdanov M.B. Oxidative stress in patients with Friedreich ataxia [see comments]. Neurology 2000, 55:1719-1721.
20. Emond M., Lepage G., Vanasse M., Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia [see comments]. Neurology 2000, 55:1752-1753.
21. Seznec H., Simon D., Bouton C., Reutenauer L., Hertzog A., Golik P., Procaccio V., Patel M., Drapier J.C., Koenig M., Puccio H. Friedreich ataxia: The oxidative stress paradox. Hum. Mol. Genet. 2005, 14:463-474.
22. Sugiyama Y., Fujita T., Matsumoto M., Okamoto K., Imada I. Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J. Pharmacobiodyn. 1985, 8:1006-1017.
23. Rustin P., von Kleist-Retzow J.C., Chantrel-Groussard K., Sidi D., Munnich A., Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study. Lancet 1999, 354:477-479.
24. Hausse A.O., Aggoun Y., Bonnet D., Sidi D., Munnich A., Rotig A., Rustin P. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia [see comments]. Heart 2002, 87:346-349.
25. Fournier A., Therien J., Vanasse M., Émond M., Pandolfo M. Effect of idebenone on cardiomyopathy in Friedreich's ataxia. Can. J. Cardiol. 2001, 17(Suppl C):89C-288C.
26. Leber I., Tanguy M.L., Pousset F., Rivaud S., Jedynak P., Welter M.L., Mallet A., Brice A., Durr A. Long term follow-up of patients with Friedreich's ataxia treated with Idebenone: A French open trial for over 3 years. Freidreich's Ataxia Research Alliance 2003, (accessed November 16, 2005). http://www.faresearchalliance.org/docs/abstract003.pdf.
27. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., Di Donato S. Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial. Neurology 2003, 60:1676-1679.
28. Buyse G., Mertens L., Di Salvo g., Matthijs I., Weidemann F., Eyskens B., Goossens W., Goemans N., Sutherland G.R., Van Hove J.L. Idebenone treatment in Friedreich's ataxia: Neurological, cardiac, and biochemical monitoring. Neurology 2003, 60:1679-1681.
29. Artuch R., Aracil A., Mas A., Colome C., Rissech M., Monros E., Pineda M. Friedreich's ataxia: Idebenone treatment in early stage patients. Neuropediatrics 2002, 33:190-193.
30. Hart P.E., Lodi R., Rajagopalan B., Bradley J.L., Crilley J.G., Turner C., Blamire A.M., Manners D., Styles P., Schapira A.H., Cooper J.M. Antioxidant treatment of patients with Friedreich ataxia: Four-year follow-up. Arch. Neurol. 2005, 62:621-626.
31. Kelso G.F., Porteous C.M., Coulter C.V., Hughes G., Porteous W.K., Ledgerwood E.C., Smith R.A., Murphy M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J. Biol. Chem. 2001, 276:4588-4596.
32. Smith R.A., Porteous C.M., Gane A.M., Murphy M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA 2003, 100:5407-5412.
33. Jauslin M.L., Meier T., Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003, 17:1972-1974.
34. Jauslin M.L., Wirth T., Meier T., Schoumacher F. A cellular model for Friedreich ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum. Mol. Genet. 2002, 11:3055-3063.
35. Dawson D.A., Masayasu H., Graham D.I., Macrae I.M. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci. Lett. 1995, 185:65-69.
36. Infante J.P., Huszagh V.A. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: A common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett. 2000, 468:1-5.
37. Schols L., Zange J., Abele M., Schillings M., Skipka G., Kuntz-Hehner S., van Beekvelt M.C., Colier W.N., Muller K., Klockgether T., Przuntek H., Vorgerd M. l-Carnitine and creatine in Friedreich's ataxia: A randomized. placebo-controlled crossover trial. J. Neural Transm. 2005, 112:789-796.
38. Son L.S., Wells R.D. Triplexes, sticky DNA, and the (GAA TTC) trinucleotide repeat associated with Friedreich's ataxia. Genetic Instabilities and Neurological Diseases 2006, Ch. 21, Elsevier, Burlington, MA. 2nd ed. R.D. Wells, T. Ashizawa (Eds.).
39. Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion [see comments]. Science 1996, 271:1423-1427.
40. Pandolfo M. Molecular pathogenesis of Friedreich's ataxia. Neurol. Rev. 1999, 56:1201-1208.
41. Ohshima K., Montermini L., Wells R.D., Pandolfo M. Inhibitory effects of expanded GAA TTC triplet repeats from intron I of theFriedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem. 1998, 273:14588-14595.
42. Sakamoto N. Sticky DNA: Self-association properties of long GAA TTC repeats in R·R·Y triplex structures from Friedreich's ataxia. Mol. Cell 1999, 3:465-475.
43. Grabczyk E., Usdin K. Alleviating transcript insufficiency caused by Friedreich's ataxia triplet repeats. Nucleic Acids Res. 2000, 28:4930-4937.
44. Sarsero J.P., Li L., Wardan H., Sitte K., Williamson R., Ioannou P.A. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Gene Med. 2003, 5:72-81.
45. Gottesfeld J.M., Turner J.M., Dervan P.B. Chemical approaches to control gene expression. Gene Expr. 2000, 9:77-91.
46. Dervan P.B., Edelson B.S. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr. Opin. Struct. Biol. 2003, 13:284-299.
47. Dickinson L.A., Burnett R., Melander C., Edelson B.S., Arora P.S., Dervan P.B., Gottesfeld J.M. Arresting cancer proliferation by small-molecule gene regulation. Chem. Biol. 2004, 11:1583-1594.